Skip to Content
Merck
All Photos(1)

Key Documents

SML1657

Sigma-Aldrich

Gefitinib

≥98% (HPLC), powder, EGFR TK inhibitor

Synonym(s):

N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine, ZD1839

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H24ClFN4O3
CAS Number:
Molecular Weight:
446.90
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Pricing and availability is not currently available.

product name

Gefitinib, ≥98% (HPLC)

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

room temp

SMILES string

COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4

InChI

1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

InChI key

XGALLCVXEZPNRQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PZ0330PZ0289F5557
Fasentin ≥98% (HPLC)

F5557

Fasentin

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

room temp

storage temp.

room temp

storage temp.

room temp

storage temp.

room temp

solubility

DMSO: 10 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 10 mg/mL, clear (warmed)

solubility

DMSO: >10 mg/mL

color

white to beige

color

white to beige

color

white to beige

color

white to off-white

Application

Gefitinib has been used :
  • To study its effective use in endometrial cancer therapy[1]
  • Cell proliferation, cell cycle and apoptosis assays[2]
  • Cell viability assay and colony formation assay[3]

Biochem/physiol Actions

Gefitinib is a selective epidermal growth factor receptor tyrosine kinase (EGFR TK) inhibitor. Gefitinib has antineoplastic activity, and has been approved for the treatment on non-small cell lung cancer (NSCLC).
Gefitinib has a higher affinity for ATP (adenosine triphosphate) binding site in the EGFR tyrosine kinase domain than ATP. Hence, gefitinib is known to inhibit the progression of endometrial cancer.[1]

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


  • Certificates of Analysis (COA)

    Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

    Need A Sample COA?

    This is a sample Certificate of Analysis (COA) and may not represent a recently manufactured lot of this specific product.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    P M Ellis et al.
    Current oncology (Toronto, Ont.), 22(3), e183-e215 (2015-06-20)
    This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients-unselected, selected, and molecularly selected-in three treatment settings: first line, second line, and maintenance. Ninety-six randomized controlled trials
    Silencing of long non-coding RNA MIAT sensitizes lung cancer cells to gefitinib by epigenetically regulating miR-34a.
    Fu Y, et al.
    Frontiers in Pharmacology, 9, 82-82 (2018)
    Xiaozheng Chen et al.
    Theranostics, 11(7), 3392-3416 (2021-02-05)
    Rationale: Immune checkpoint inhibitors (ICIs) against the PD-1/PD-L1 pathway showed limited success in non-small cell lung cancer (NSCLC) patients, especially in those with activating epidermal growth factor receptor (EGFR) mutations. Elucidation of the mechanisms underlying EGFR-mediated tumor immune escape and
    Roy S Herbst et al.
    The oncologist, 7 Suppl 4, 9-15 (2002-08-31)
    Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less
    The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma.
    Qiu M, et al.
    Cancer Research, 78(11), 2839-2851 (2018)

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service